233 related articles for article (PubMed ID: 23288484)
1. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
[TBL] [Abstract][Full Text] [Related]
3. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
9. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
10. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
McCann GA; Smith B; Backes FJ; Rath K; Chacko S; Salani R; Eisenhauer E; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2012 Nov; 127(2):362-6. PubMed ID: 22885866
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in ovarian cancer.
Mountzios G; Pentheroudakis G
N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
[No Abstract] [Full Text] [Related]
12. Bevacizumab in ovarian cancer.
Copur MS; Obermiller AM; Ramaekers R
N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
[No Abstract] [Full Text] [Related]
13. Bevacizumab in ovarian cancer.
Korn EL; Freidlin B; Abrams JS
N Engl J Med; 2012 Mar; 366(13):1256; author reply 1257-8. PubMed ID: 22455428
[No Abstract] [Full Text] [Related]
14. A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
[TBL] [Abstract][Full Text] [Related]
20. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]